Compile Data Set for Download or QSAR
Found 119 Enz. Inhib. hit(s) with all data for assayid = 1 entry = 7833
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221860(US9314468, Table 7, Compound 147)copy SMILEScopy InChI
Affinity DataIC50: 1nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221760(US9314468, Table 7, Compound 47)copy SMILEScopy InChI
Affinity DataIC50: 1nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221834(US9314468, Table 7, Compound 121)copy SMILEScopy InChI
Affinity DataIC50: 4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221796(US9314468, Table 7, Compound 83)copy SMILEScopy InChI
Affinity DataIC50: 4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221857(US9314468, Table 7, Compound 144)copy SMILEScopy InChI
Affinity DataIC50: 4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221854(US9314468, Table 7, Compound 141)copy SMILEScopy InChI
Affinity DataIC50: 5nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221808(US9314468, Table 7, Compound 95 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 7nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221853(US9314468, Table 7, Compound 140)copy SMILEScopy InChI
Affinity DataIC50: 9nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221793(US9314468, Table 7, Compound 80)copy SMILEScopy InChI
Affinity DataIC50: 9nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221738(US9314468, Table 7, Compound 25)copy SMILEScopy InChI
Affinity DataIC50: 10nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221800(US9314468, Table 7, Compound 87)copy SMILEScopy InChI
Affinity DataIC50: 11nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221761(US9314468, Table 7, Compound 48 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 12nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221832(US9314468, Table 7, Compound 119)copy SMILEScopy InChI
Affinity DataIC50: 13nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221858(US9314468, Table 7, Compound 145)copy SMILEScopy InChI
Affinity DataIC50: 14nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221775(US9314468, Table 7, Compound 62)copy SMILEScopy InChI
Affinity DataIC50: 15nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221783(US9314468, Table 7, Compound 70 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 15nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221783(US9314468, Table 7, Compound 70 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 16nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221825(US9314468, Table 7, Compound 112 | US9314468, Tabl...)copy SMILEScopy InChI
Affinity DataIC50: 17nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221740(US9314468, Table 7, Compound 27)copy SMILES
Affinity DataIC50: 18nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221825(US9314468, Table 7, Compound 112 | US9314468, Tabl...)copy SMILEScopy InChI
Affinity DataIC50: 18nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221856(US9314468, Table 7, Compound 143)copy SMILEScopy InChI
Affinity DataIC50: 20nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221851(US9314468, Table 7, Compound 138)copy SMILEScopy InChI
Affinity DataIC50: 20nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221808(US9314468, Table 7, Compound 95 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 21nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221827(US9314468, Table 7, Compound 114)copy SMILEScopy InChI
Affinity DataIC50: 21nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221769(US9314468, Table 7, Compound 56 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 22nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221769(US9314468, Table 7, Compound 56 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 22nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221744(US9314468, Table 7, Compound 31)copy SMILEScopy InChI
Affinity DataIC50: 22nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221871(US9314468, Table 8, Compound 9 | US9314468, Table ...)copy SMILEScopy InChI
Affinity DataIC50: 24nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221819(US9314468, Table 7, Compound 106)copy SMILEScopy InChI
Affinity DataIC50: 24nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221840(US9314468, Table 7, Compound 127)copy SMILEScopy InChI
Affinity DataIC50: 26nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221785(US9314468, Table 7, Compound 72 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 30nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221755(US9314468, Table 7, Compound 42)copy SMILES
Affinity DataIC50: 30nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221785(US9314468, Table 7, Compound 72 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 30nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221848(US9314468, Table 7, Compound 135)copy SMILEScopy InChI
Affinity DataIC50: 30nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221801(US9314468, Table 7, Compound 88)copy SMILEScopy InChI
Affinity DataIC50: 31nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221803(US9314468, Table 7, Compound 90 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 37nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221729(US9314468, Table 7, Compound 16)copy SMILES
Affinity DataIC50: 38nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221788(US9314468, Table 7, Compound 75)copy SMILEScopy InChI
Affinity DataIC50: 44nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221884(US9314468, Table 9, Compound 6)copy SMILEScopy InChI
Affinity DataIC50: 44nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221847(US9314468, Table 7, Compound 134)copy SMILEScopy InChI
Affinity DataIC50: 44nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221852(US9314468, Table 7, Compound 139)copy SMILEScopy InChI
Affinity DataIC50: 44nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221836(US9314468, Table 7, Compound 123)copy SMILEScopy InChI
Affinity DataIC50: 47nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221859(US9314468, Table 7, Compound 146)copy SMILEScopy InChI
Affinity DataIC50: 49nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221814(US9314468, Table 7, Compound 101 | US9314468, Tabl...)copy SMILEScopy InChI
Affinity DataIC50: 55nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221820(US9314468, Table 7, Compound 107)copy SMILEScopy InChI
Affinity DataIC50: 56nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221876(US9314468, Table 8, Compound 14 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 56nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221763(US9314468, Table 7, Compound 50)copy SMILEScopy InChI
Affinity DataIC50: 57nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221803(US9314468, Table 7, Compound 90 | US9314468, Table...)copy SMILEScopy InChI
Affinity DataIC50: 59nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221822(US9314468, Table 7, Compound 109)copy SMILEScopy InChI
Affinity DataIC50: 61nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics, Inc.

US Patent
LigandPNGBDBM221814(US9314468, Table 7, Compound 101 | US9314468, Tabl...)copy SMILEScopy InChI
Affinity DataIC50: 63nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2DF6Q2PUS Patent
Displayed 1 to 50 (of 119 total ) | Next | Last >>
Jump to: